Updates from guardian™: a comprehensive registration programme

Area of Science:

• Haematology
• Pharmacology
• Clinical Trials

Background:

• Haemophilia A is a genetic bleeding disorder caused by factor VIII deficiency.
• Turoctocog alfa is a B-domain truncated recombinant factor VIII concentrate.
• Previous treatments have limitations, necessitating improved therapeutic options.

Purpose of the Study:

• To review the clinical development and efficacy of turoctocog alfa.
• To present safety and efficacy data from the guardian clinical program.
• To assess the long-term outcomes of turoctocog alfa treatment.

Main Methods:

• Phase III clinical trials (guardian 1, 2, and 3) involving previously treated severe haemophilia A patients.
• Prophylactic treatment with turoctocog alfa three times weekly or every second day.
• Monitoring of bleeding events, inhibitor development, and haemostatic response.

Main Results:

• No safety concerns or confirmed inhibitor development in over 200 patients and 54,000 exposure days.
• Significant reduction in annualized bleeding rate.
• 86% success rate for haemostatic response, with 90% of bleeds resolved in 1-2 doses.

Conclusions:

• Turoctocog alfa demonstrates a favorable safety profile and efficacy in managing haemophilia A.
• The guardian clinical program supports the use of turoctocog alfa for prophylaxis and bleed resolution.
• Long-term data indicate sustained effectiveness and safety in adult and pediatric populations.